<trans-title xml:lang="en"/>_West China Medical Journal

Authors：

, , , , 

德陽市人民醫院病理科（四川德陽 618000）;

Corresponding?author：

, Email: holly.tony@163.com

Keywords：

雌激素受體; 孕激素受體; Ki-67; 淋巴結轉移; 乳腺癌; 相關性

DOI：

10.7507/1002-0179.201505173

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的探討雌激素受體（estrogen receptor，ER）、孕激素受體（progesterone receptor，PR）及細胞核增殖抗原 Ki-67 表達與乳腺癌淋巴結轉移的相關性。方法選取 2010 年 1 月—2014 年 12 月收治的 593 例乳腺癌手術切除患者，術后腫瘤石蠟組織常規行 ER、PR、Ki-67 檢測，將這些分子的表達與淋巴結轉移情況進行比較與分析。結果 593 例患者中 ER、PR 的陽性表達率分別為 66.78%、56.32%，Ki-67 指數>14% 的患者占 70.82%；淋巴結轉移陽性率為 47.22%；ER 的表達與淋巴結轉移存在相關性（P<0.05），PR 和 Ki-67 的表達與淋巴結轉移不存在相關性（P>0.05）。結論 ER 的表達與淋巴結轉移相關，PR、Ki-67 的表達與淋巴結轉移不相關。

Citation： 何小艷, 成永蓮, 李慧, 徐培, 吳寧. . West China Medical Journal, 2017, 32(2): 226-228. doi: 10.7507/1002-0179.201505173 Copy

1.	?Hammond ME, Hayes DF, Dowser M, et al. American Society of Clinical Oncology/College of American Pathologists guaidline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol, 2010, 28(16): 2784-2795.
2.	劉紅艷, 宋豐舉, 雷蕾, 等. 1267 例乳腺癌臨床與免疫組化指標的相關性分析.中國腫瘤臨床, 2011, 38(11): 656-659.
3.	Oldhirseh A, Wood WC, Coates AS, et al. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 2011, 22(8): 1736-1747.
4.	朱學強, 任剛, 胡洪林. 乳腺癌組織中 VEGF、C-erbB-2、P53 及 Ki67 的表達與臨床意義. 西部醫學, 2009, 21(3): 427-429.
5.	Shi XB, Wang L. Treatment for triple-negative breast cancer. Chinese-German J Clin Oncol, 2012, 11(9): 539-543.
6.	張慶莉, 張慶慧, 叢華, 等. BRCAl 和 WWOX 在年輕女性乳腺浸潤性導管癌中的表達及臨床病理意義. 中華病理學雜志, 2013, 42(2): 90-94.
7.	Zhu X, Ying J, Wang F, et al. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China. Breast Cancer Res Treat, 2014, 147(3): 551-555.
8.	臧鳳琳, 魏熙胤, 孫蕾娜, 等. c-FLIP(L) 在乳腺癌中表達的意義及對凋亡的調節. 中國腫瘤臨床, 2010, 37(15): 841-845.
9.	Ogawa Y, Moriya T, Kato Y, et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer, 2004, 11(3): 267-275.
10.	Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 ex-pression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst, 2007, 99(2): 167-170.
11.	Bhatavdekar JM, Patel DD, Shah NG, et al. Prognostic significance of immunohistochemically localized biomarkers in stage Ⅱ and stage Ⅲ breast cancer: a multivariate analysis. Ann Surg Oncol, 2000, 7(4): 305-311.
12.	李寶江, 朱志華, 王軍業, 等. Ki67、P53、VEGF 和 C-erbB-2 在乳腺癌組織中表達的相關性研究及其臨床意義. 癌癥, 2004, 23(10): 1176-1179.
13.	Nishimura R, Osako T, Okumura Y, et al. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med, 2010, 1(5): 747-754.
14.	Molino A, Micciolo R, Turazza M, et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer, 1997, 74(4): 433-437.
15.	樸正日, 金全金, 申龍河. Ki67 在乳腺癌組織中表達及其與 C-erbB-2、ER、PR、P53 基因的關系. 中國民康醫學, 2010, 22(3): 258-260, 265.

1. ?Hammond ME, Hayes DF, Dowser M, et al. American Society of Clinical Oncology/College of American Pathologists guaidline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol, 2010, 28(16): 2784-2795.
2. 劉紅艷, 宋豐舉, 雷蕾, 等. 1267 例乳腺癌臨床與免疫組化指標的相關性分析.中國腫瘤臨床, 2011, 38(11): 656-659.
3. Oldhirseh A, Wood WC, Coates AS, et al. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 2011, 22(8): 1736-1747.
4. 朱學強, 任剛, 胡洪林. 乳腺癌組織中 VEGF、C-erbB-2、P53 及 Ki67 的表達與臨床意義. 西部醫學, 2009, 21(3): 427-429.
5. Shi XB, Wang L. Treatment for triple-negative breast cancer. Chinese-German J Clin Oncol, 2012, 11(9): 539-543.
6. 張慶莉, 張慶慧, 叢華, 等. BRCAl 和 WWOX 在年輕女性乳腺浸潤性導管癌中的表達及臨床病理意義. 中華病理學雜志, 2013, 42(2): 90-94.
7. Zhu X, Ying J, Wang F, et al. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China. Breast Cancer Res Treat, 2014, 147(3): 551-555.
8. 臧鳳琳, 魏熙胤, 孫蕾娜, 等. c-FLIP(L) 在乳腺癌中表達的意義及對凋亡的調節. 中國腫瘤臨床, 2010, 37(15): 841-845.
9. Ogawa Y, Moriya T, Kato Y, et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer, 2004, 11(3): 267-275.
10. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 ex-pression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst, 2007, 99(2): 167-170.
11. Bhatavdekar JM, Patel DD, Shah NG, et al. Prognostic significance of immunohistochemically localized biomarkers in stage Ⅱ and stage Ⅲ breast cancer: a multivariate analysis. Ann Surg Oncol, 2000, 7(4): 305-311.
12. 李寶江, 朱志華, 王軍業, 等. Ki67、P53、VEGF 和 C-erbB-2 在乳腺癌組織中表達的相關性研究及其臨床意義. 癌癥, 2004, 23(10): 1176-1179.
13. Nishimura R, Osako T, Okumura Y, et al. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med, 2010, 1(5): 747-754.
14. Molino A, Micciolo R, Turazza M, et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer, 1997, 74(4): 433-437.
15. 樸正日, 金全金, 申龍河. Ki67 在乳腺癌組織中表達及其與 C-erbB-2、ER、PR、P53 基因的關系. 中國民康醫學, 2010, 22(3): 258-260, 265.

Previous Article
Next Article
Analysis on the management of laboratory critical values in the Department of Cardiovascular Surgery

West China Medical Journal

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content